BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen S, Dean DC, Yu Z, Duan Z. Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. Hepatol Res 2019;49:1097-108. [PMID: 31009153 DOI: 10.1111/hepr.13353] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
Number Citing Articles
1 Golkowski M, Lau HT, Chan M, Kenerson H, Vidadala VN, Shoemaker A, Maly DJ, Yeung RS, Gujral TS, Ong SE. Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Syst 2020;11:196-207.e7. [PMID: 32755597 DOI: 10.1016/j.cels.2020.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zhang J, Zhang X, Huang H, Ding Y. A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II-Biological functions and inhibitors. Bioorg Chem 2020;104:104318. [PMID: 33142427 DOI: 10.1016/j.bioorg.2020.104318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li JJ, Yan YY, Sun HM, Liu Y, Su CY, Chen HB, Zhang JY. Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review. Front Pharmacol 2019;10:746. [PMID: 31354475 DOI: 10.3389/fphar.2019.00746] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
4 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
5 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Zhu Y, Ke KB, Xia ZK, Li HJ, Su R, Dong C, Zhou FM, Wang L, Chen R, Wu SG, Zhao H, Gu P, Leung KS, Wong MH, Lu G, Zhang JY, Jiang BH, Qiu JG, Shi XN, Lin MC. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma. Mol Med 2021;27:15. [PMID: 33579185 DOI: 10.1186/s10020-021-00269-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Huo D, Jiang S, Qin Z, Feng Y, Yang R, Lv L, Li Y. Omethoate induces pharyngeal cancer cell proliferation and G1/S cell cycle progression by activation of Akt/GSK-3β/cyclin D1 signaling pathway. Toxicology 2019;427:152298. [DOI: 10.1016/j.tox.2019.152298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
8 Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka MS, Kawaji H, Shiozawa K, Machitani M, Abe T, Yamada S, Kaneko MK, Kato Y, Furuta Y, Kondo T, Shirouzu M, Hayashizaki Y, Kaneko S, Masutomi K. CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nat Commun 2020;11:1557. [PMID: 32214089 DOI: 10.1038/s41467-020-15289-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wang Y, Song F, Zhang X, Yang C, Zhang J. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-28. [DOI: 10.1155/2022/1592905] [Reference Citation Analysis]
10 Zhang X, Wang Q, Luo Y, Song M, Zhou Z, Zeng L, Hu M, Yang C. Cyclin-dependent kinase 15 upregulation is correlated with poor prognosis for patients with breast cancer. J Int Med Res 2021;49:300060521999552. [PMID: 34162268 DOI: 10.1177/0300060521999552] [Reference Citation Analysis]
11 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
12 Masaki T, Morishita A. Previous and current knowledge on cell cycle‐related molecules in hepatocellular carcinoma: Potential therapeutic targets of cell cycle‐related molecules in hepatocellular carcinoma. Hepatol Res 2019;49:1094-6. [DOI: 10.1111/hepr.13440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Digiacomo G, Fumarola C, La Monica S, Bonelli MA, Cretella D, Alfieri R, Cavazzoni A, Galetti M, Bertolini P, Missale G, Petronini PG. Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Front Oncol 2020;10:563249. [PMID: 33072590 DOI: 10.3389/fonc.2020.563249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]